相关临床试验
126
37 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
1840
进行中（未招募）
7
5.6%
已完成
54
42.9%
尚未招募
30
23.8%
招募中
30
23.8%
终止
3
2.4%
Unknown
1
0.8%
撤回
1
0.8%
- Adelaide University researchers led by Professor Ivan Kempson received $240,000 from the Mark Hughes Foundation Centre for Brain Cancer Research to study how radiation affects brain cancer at a cellular level. - The project uses first-of-their-kind tools in Australia to measure radiation-induced DNA damage with unprecedented precision, aiming to enhance tumor cell damage while protecting healthy tissue. - The team is also investigating how radiation influences the immune system, working with clinicians at the Royal Adelaide Hospital in a real-world treatment environment. - Brain cancer survival rates have changed little in 35 years, with only two in 10 patients surviving beyond five years, underscoring the urgent need for improved treatment approaches.
- South Australia will establish a dedicated CAR T-cell therapy service at Royal Adelaide Hospital by mid-2026, with $2.8 million allocated in the 2025-26 budget for this cutting-edge blood cancer treatment. - The service will initially treat four patients in the first year, scaling up over time to reduce the need for approximately 30 South Australian patients who currently travel interstate annually for this specialized therapy. - CAR T-cell therapy involves collecting and genetically modifying a patient's own T-cells to target cancer cells, offering new hope for individuals with hard-to-treat blood cancers including relapsed lymphoma and acute lymphoblastic leukemia. - The establishment follows advocacy efforts by Adelaide resident Steph Walker, whose father received successful CAR T-cell treatment in Melbourne but faced significant logistical challenges and family disruption during the interstate treatment process.
- Aethlon Medical successfully treated the first three patients in its Hemopurifier cancer trial at Australian hospitals, with all participants completing 4-hour treatments without device deficiencies or immediate complications. - The company received regulatory approval from India's Central Drugs Standard Control Organization to initiate a similar oncology study at Medanta Medicity Hospital. - Preclinical data demonstrated 98.5% removal of platelet-derived extracellular vesicles, supporting potential applications in multiple diseases including cancer, Long COVID, and autoimmune conditions. - The trial protocol was expanded to include patients receiving combination therapies with Pembrolizumab or Nivolumab, reflecting current immunotherapy treatment practices.
- Aethlon Medical successfully treated a second patient with its investigational Hemopurifier device in an Australian clinical trial targeting solid tumors resistant to anti-PD-1 therapies. - Both patients in the first cohort completed 4-hour treatments without device deficiencies or immediate complications, with safety data to be reviewed by an independent Data Safety Monitoring Board. - The approximately 18-patient trial aims to evaluate whether removing tumor-derived extracellular vesicles can improve response rates to pembrolizumab or nivolumab, which currently show lasting responses in only 30-40% of patients. - The Hemopurifier holds FDA Breakthrough Device designation and is designed to bind and remove extracellular vesicles implicated in cancer metastasis and immunotherapy resistance.
